首个“中国籍”地舒单抗在美获批上市！复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场

智通财经09-02

【首个“中国籍”地舒单抗在美获批上市！复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场】智通财经APP讯，9月2日，复宏汉霖(02696.HK)与Organon(OGN)今日共同宣布，美国食品药品监督管理局(FDA)已批准地舒单抗注射液(60mg/mL)BILDYOS®(denosumab-nxxp)和地舒单抗注射液(120mg/1.7mL)BILPREVDA®(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2564805704?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-02 18:32","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2564805704","market":"us","top_or_hot":-1,"title":"首个“中国籍”地舒单抗在美获批上市！复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场","media":"智通财经","content":"<div>\n<p>【首个“中国籍”地舒单抗在美获批上市！复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场】智通财经APP讯，9月2日，复宏汉霖(02696.HK)与Organon(OGN)今日共同宣布，美国食品药品监督管理局(FDA)已批准地舒单抗注射液(60mg/mL)BILDYOS®(denosumab-nxxp)和地舒单抗注射液(120mg/1.7mL)BILPREVDA®(...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>首个“中国籍”地舒单抗在美获批上市！复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n首个“中国籍”地舒单抗在美获批上市！复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-02 18:32 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=ganggu><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【首个“中国籍”地舒单抗在美获批上市！复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场】智通财经APP讯，9月2日，复宏汉霖(02696.HK)与Organon(OGN)今日共同宣布，美国食品药品监督管理局(FDA)已批准地舒单抗注射液(60mg/mL)BILDYOS®(denosumab-nxxp)和地舒单抗注射液(120mg/1.7mL)BILPREVDA®(...</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2564805704","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564805704","pubTimestamp":1756809132,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【首个“中国籍”地舒单抗在美获批上市！复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场】智通财经APP讯，9月2日，复宏汉霖(02696.HK)与Organon(OGN)今日","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK4585":"ETF&股票定投概念","BK4559":"巴菲特持仓","02696":"复宏汉霖","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4007":"制药","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","OGN":"Organon & Co","BK4588":"碎股"},"translate_title":"The first \"Chinese nationality\" denosumab was approved for marketing in the United States! Henlius (02696. HK) joins hands with Organon to explore the key bone care treatment market in the United States","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OGN":1,"02696":1},"content_text":"【首个“中国籍”地舒单抗在美获批上市！复宏汉霖(02696.HK)携手Organon开拓美国关键骨骼护理治疗市场】智通财经APP讯，9月2日，复宏汉霖(02696.HK)与Organon(OGN)今日共同宣布，美国食品药品监督管理局(FDA)已批准地舒单抗注射液(60mg/mL)BILDYOS®(denosumab-nxxp)和地舒单抗注射液(120mg/1.7mL)BILPREVDA®(denosumab-nxxp)的上市申请。两款产品分别为PROLIA®(denosumab)和XGEVA®(denosumab)的生物类似药，此次获批复盖原研产品在美国已获批的所有适应症。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2564805704","isCrawlerRequest":true}